US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% NVDA $215.38 ▼-1.17% GOOGL $324.89 ▲+1.34% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66% MSFT $531.01 ▼-0.06%
FinancialContent

Bristol-Myers Squibb (NY:BMY)

60.57 -0.98 (-1.59%)
Official Closing Price Updated: 4:10 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
95 96 Next >
News headline image
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
PacBio, Bristol-Myers Squibb, Oscar Health, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after a Politico report revealed that the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies... 
Via StockStory
Topics Economy
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices ↗
Via Stocktwits
Topics Workforce
News headline image
Monday's session: gap up and gap down stock in the S&P500 index ↗
Curious about the S&P500 stocks that are gapping on Monday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
News headline image
Which S&P500 stocks are moving before the opening bell on Monday? ↗
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Bristol Myers Squibb to Host Hematology-Focused Investor Event
From Bristol Myers Squibb
Via Business Wire
News headline image
What's Driving the Market Sentiment Around Bristol-Myers Squibb Co? ↗
 
Via Benzinga
News headline image
Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗
Via MarketBeat
News headline image
Market Movers in Motion: Merck & Co. and Amer Sports Chart Volatile Courses
The financial markets are a constant theater of dynamic shifts, and in recent months, two distinct players – pharmaceutical giant Merck & Co. and global sporting goods powerhouse Amer Sports – have... 
Via MarketMinute
Topics Economy Initial Public Offering Intellectual Property
News headline image
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
From Bristol Myers Squibb
Via Business Wire
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q3
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Bristol-Myers Squibb (NYSE:BMY) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Cash-Producing Stock to Keep an Eye On and 2 We Find Risky
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
These 2 Dividend ETFs Are a Retiree's Best Friend ↗
Exchange-traded funds provide investors with exposure to a basket of stocks. Some also pay dividends. 
Via The Motley Fool
Topics Artificial Intelligence Bonds ETFs
News headline image
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks ↗
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Stay informed with the top movers within the S&P500 index on Friday. ↗
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Discover which S&P500 stocks are making waves on Friday. ↗
Stay informed about the performance of the S&P500 index in the middle of the day on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Tech Rebounds After Selloff, Bitcoin Craters To $97,000: What's Moving Markets Friday? ↗
Investors stepped back into beaten-down tech names Friday, with the Nasdaq 100 rising 0.6% by midday in New York, staging a modest rebound after Thursday's sharp selloff. 
Via Benzinga
News headline image
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy ↗
Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026. 
Via Benzinga
News headline image
Friday's session: gap up and gap down stock in the S&P500 index ↗
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Friday to find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Bristol Myers Slumps After Its Heart Condition Study Gets The Boot ↗
An independent data monitoring committee said the company's treatment for acute coronary syndrome was likely to fail in testing. 
Via Investor's Business Daily
News headline image
Discover the top S&P500 movers in Friday's pre-market session. ↗
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
BMY Stock Slumps 5% After It Scraps Heart Drug Study ↗
The decision follows an analysis by an independent data monitoring committee that the trial is unlikely to meet its key goal. 
Via Stocktwits
News headline image
Update on Phase 3 Librexia ACS Trial
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Reasons to Avoid BMY and 1 Stock to Buy Instead
While the S&P 500 is up 16.3% since May 2025, Bristol-Myers Squibb (currently trading at $48.73 per share) has lagged behind, posting a return of 10.4%. This might have investors contemplating their... 
Via StockStory
Topics Stocks
News headline image
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run ↗
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership. 
Via Benzinga
News headline image
3 Healthcare Stocks Topping a 2025 List of Dividend Yields ↗
Turn health into wealth with these three high-yielding dividend stocks. 
Via The Motley Fool
News headline image
Jim Cramer Is Backing Off Bristol-Myers, But These 2 Chinese Stocks Are Good ↗
"Mad Money" host Jim Cramer discusses Bristol-Myers Squibb, Baidu, Alibaba, Brinker and New Era Energy & Digital. 
Via Benzinga
News headline image
Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern
San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results... 
Via MarketMinute
News headline image
Cliff Asness: The Stock Market is Expensive, Not a Bubble – A Call for Rationality in a Less Efficient Market
New York, NY – November 10, 2025 – In a financial landscape often characterized by extremes, Cliff Asness, the influential co-founder of AQR Capital Management, offers a nuanced yet stark assessment of... 
Via MarketMinute
Topics Economy
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
95 96 Next >